View Older Stories
-
Freedom Broker Upgrades Amgen (AMGN) to Buy
-
Erste Group Downgrades Amgen (AMGN) to Hold
-
AMGEN announces $300 million US manufacturing investment
-
Amgen (AMGN) PT Lowered to $340 at Guggenheim
-
Amgen (AMGN) PT Raised to $307 at BofA Securities
-
Amgen (AMGN) Tops Q1 EPS by 35c, Offers Guidance
-
Amgen (AMGN) call put ratio 1.5 calls to 1 put with a focus on May 365 calls into quarter results
-
Amgen (AMGN) call put ratio 1.6 calls to 1 put into quarter results
-
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
-
Canaccord Starts Amgen (AMGN) at Hold
-
Amgen (AMGN) PT Raised to $400 at UBS
-
Amgen (AMGN) PT Raised to $351 at Guggenheim
-
Amgen (AMGN) PT Raised to $325 at Truist Securities
-
Amgen (AMGN) Reiterated at Neutral by Cantor Fitzgerald Amid Negative/Neutral Sentiment
-
William Blair on Amgen (AMGN): top-line results show 'strong efficacy' compared to VRDN data
-
Stifel on Viridian (VRDN): 'We view positive REVEAL-2 chronic TED data in 2Q26 as important'
-
RBC Capital: 'Amgen (AMGN) Highlights Key Growth Drivers For The Rest Of 2026 And Beyond'
-
Amgen’s Tavneos Tied to Deaths, Liver Injury - FDA
-
Jefferies on Amgen (AMGN): Elegrobart data not a 'significant competitive threat to Tepezza'
-
Jefferies Starts Amgen (AMGN) at Hold
-
Jefferies Starts Vertex (VRTX) at Buy
-
Jefferies Starts Gilead Sciences (GILD) at Buy
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
Leerink Partners Reiterates Market Perform Rating on Amgen (AMGN), lowers estimates
-
Amgen (AMGN) Declares $2.52 Quarterly Dividend; 2.7% Yield
-
Barclays Starts Amgen (AMGN) at Equalweight
-
TD Cowen on Amgen's (AMGN) Dazodalibep: 'An Overlooked Gem In Amgen's Pipeline?'
-
Amgen (AMGN) PT Raised to $432 at Piper Sandler
-
Amgen (AMGN) files mixed shelf
-
Freedom Capital Markets Downgrades Amgen (AMGN) to Hold (mid morning)
-
Amgen (AMGN) PT Raised to $347 at Guggenheim
-
BofA on Amgen (AMGN): 'Catalysts: pelacarsen readthrough shifts to mid-2026'
-
Amgen (AMGN) PT Raised to $350 at Cantor Fitzgerald
-
Amgen (AMGN) PT Raised to $360 at RBC Capital
-
Amgen (AMGN) PT Raised to $420 at TD Cowen
-
After-hours movers: AMD, Chipotle, Lumentum, Silicon Labs and more
-
Amgen (AMGN) Tops Q4 EPS by 56c, Beats on Revenue; Offers FY26 Guidance
-
Amgen (AMGN) call put ratio 1 call to 1 put into quarter results
-
Amgen (AMGN) call put ratio 1.1 calls to 1 put into quarter results
-
Amgen (AMGN) call put ratio 2.3 calls to 1 put into quarter results
-
Amgen (AMGN) call put ratio 1 call to 1.4 puts into quarter results
-
Amgen (AMGN) call put ratio 1 call to 1.6 puts into quarter results
-
This U.S. biotech stock is Bernstein's Top Pick for 2026
-
Bernstein SocGen Group Downgrades Amgen (AMGN) to Market Perform
-
Amgen (AMGN) PT Raised to $304 at BofA Securities
-
Amgen (AMGN) call put ratio 1 call to 5.3 puts into the annual J.P. Morgan Healthcare Conference
-
UBS Assumes Amgen (AMGN) at Buy
-
Amgen acquires Dark Blue Therapeutics for up to $840 million
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
Here's the list of top biotech stocks to own for 2026

